Anna D. Staniszewska

机构：AstraZeneca (United Kingdom), Target (United States), Cancer Targeted Technology (United States), AstraZeneca (Singapore), Abzena (United Kingdom) · ORCID：0000-0003-1328-1959

发表论文 153 篇 · 总被引 1959 次 · h-index 20

代表论文

• The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models (2024 · Genome Medicine · 被引 69)
• Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}- N -methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor (2024 · Journal of Medicinal Chemistry · 被引 32)
• Homologous recombination deficiency and hemizygosity drive resistance in breast cancer (2026 · Nature · 被引 6)
• Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair (2025 · NAR Cancer · 被引 6)
• NF-κB-Inducing Kinase Is Essential for Effective c-Rel Transactivation and Binding to the Il12b Promoter in Macrophages (2025 · Biology · 被引 2)
• An inducible BRCA1 expression system with in vivo applicability uncovers activity of the combination of ATR and PARP inhibitors to overcome therapy resistance (2025 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 1)